# Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

> **NCT04335682** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Alliance Foundation Trials, LLC.** · enrollment: 111 (actual)

## Conditions studied

- Metastatic Prostate Cancer
- Prostate Cancer Metastatic
- Prostate Cancer
- Castrate Resistant Prostate Cancer
- Hormone Sensitive Prostate Cancer
- Non-metastatic Prostate Cancer

## Interventions

- **DRUG:** Darolutamide
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT04335682
- **Lead sponsor:** Alliance Foundation Trials, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-17
- **Primary completion:** 2025-09-01
- **Final completion:** 2026-08
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2025-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04335682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04335682, "Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04335682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*